-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
There are basic coronary and cerebral vascular disease patients often require lifelong use of aspirin, but this may lead to digestive ulcer disease (PUD) and digestive tract hemorrhage
.
Generally, the risk of bleeding can be minimized by using proton pump inhibitors (PPI) at the same time.
At the same time, clopidogrel is an alternative antiplatelet drug with fewer upper gastrointestinal bleeding events and higher cardiovascular safety
There are basic coronary and cerebral vascular disease patients often require lifelong use of aspirin, but this may lead to digestive ulcer disease (PUD) and digestive tract hemorrhage
This study included adult patients at high risk of developing UGIB after aspirin-related bleeding between 2000 and 2012
.
prevention
Among the 947 eligible patients, 653 repeated aspirin (combined with proton pump inhibitor) and 294 received clopidogrel (combined with proton pump inhibitor) after being discharged from the hospital due to UGIB
.
Compared with aspirin treatment, clopidogrel was associated with increased risks of MACE ([aHR] 1.
65; 95% [CI] 0.
Figure: The effect of aspirin on gastrointestinal bleeding
In this study, it was found that there was no significant difference between clopidogrel and aspirin in short-term MACE prevention and UGIB recurrence
.
.
Original source:
Shih-Cheng Yang.
Et al.
Risks of adverse events for users of proton-pump inhibitors plus aspirin or clopidogrel in patients with aspirin-related ulcer bleeding.
Leave a message here
